Prognostic markers of all-cause mortality in patients with atrial fibrillation: data from the prospective long-term registry of the German Atrial Fibrillation NETwork (AFNET).

AF type Atrial fibrillation Comorbidities German AFNET registry Mortality Outcome Prognostic factors

Journal

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology
ISSN: 1532-2092
Titre abrégé: Europace
Pays: England
ID NLM: 100883649

Informations de publication

Date de publication:
07 12 2021
Historique:
received: 09 02 2021
accepted: 15 04 2021
pubmed: 18 6 2021
medline: 1 4 2022
entrez: 17 6 2021
Statut: ppublish

Résumé

Atrial fibrillation (AF) is associated with a high risk of cardiovascular and non-cardiovascular death, even on anticoagulation. It is controversial, which conditions-including concomitant diseases and AF itself-contribute to this mortality. To further clarify these questions, major determinants of long-term mortality and their contribution to death were quantified in an unselected cohort of AF patients. We established a large nationwide registry comprising 8833 AF-patients with a median follow-up of 6.5 years (45 345 patient-years) and central adjudication of adverse events. Baseline characteristics of the patients were evaluated as predictors of mortality using Cox regression and C-indices for determination of predictive power. Annualized mortality was highest in the first year (6.2%) and remained high thereafter (5.2% in men and 5.5% in women). Thirty-eight percent of all deaths were cardiovascular, mainly due to heart failure or sudden death. Sex-specific age was the strongest predictor of mortality, followed by concomitant cardiovascular and non-cardiovascular conditions. These factors accounted for 25% of the total mortality beyond age and sex and for 84% of the mortality differences between AF types. Thus, the electrical phenotype of the disease at baseline contributed only marginally to prediction of mortality. Mortality is high in AF patients and arises primarily from heart failure, peripheral artery disease, chronic obstructive lung disease, chronic kidney disease, and diabetes mellitus, which, therefore, should be targeted to lower mortality. Parameters related to the electrical manifestation of AF did not have an independent impact on long-term mortality in our representative cohort.

Identifiants

pubmed: 34136917
pii: 6301173
doi: 10.1093/europace/euab113
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1903-1912

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2021. For permissions, please email: journals.permissions@oup.com.

Auteurs

Michael Nabauer (M)

Medical Clinic I, Ludwig-Maximilians-University, Campus Grosshadern, Marchioninistr. 15, D-81377 Munich, Germany.

Michael Oeff (M)

Department of Medicine I, Brandenburg Municipal Hospital, Brandenburg, Germany.

Andrea Gerth (A)

Medical Clinic I, Ludwig-Maximilians-University, Campus Grosshadern, Marchioninistr. 15, D-81377 Munich, Germany.

Karl Wegscheider (K)

Department of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Anika Buchholz (A)

Department of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Karl Georg Haeusler (KG)

Department of Neurology, Universitätsklinikum Würzburg, Würzburg, Germany.

Peter Hanrath (P)

Medical Clinic I, University Hospital RWTH, Aachen, Germany.

Thomas Meinertz (T)

Department of Cardiology/Angiology, University Hospital Eppendorf, Hamburg, Germany.

Ursula Ravens (U)

Institute for Experimental Cardiovascular Medicine, University Heart Center, University of Freiburg, Freiburg, Germany.
Institute of Physiology, Medical Faculty Carl Gustav Carus, TU Dresden, Dresden, Germany.

Claudia Sprenger (C)

Department of Medicine I, Brandenburg Municipal Hospital, Brandenburg, Germany.

Ulrich Tebbe (U)

Department of Cardiology, Hospital Detmold, Detmold, Germany.

Eik Vettorazzi (E)

Department of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Paulus Kirchhof (P)

Department of Cardiology/Angiology, University Hospital Eppendorf, Hamburg, Germany.

Günter Breithardt (G)

Department of Cardiovascular Medicine, University Hospital Münster, Münster, Germany.

Gerhard Steinbeck (G)

Medical Clinic I, Ludwig-Maximilians-University, Campus Grosshadern, Marchioninistr. 15, D-81377 Munich, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH